Cargando…
Analysis of the efficacy and influencing factors of preoperative P‐SOX neoadjuvant chemotherapy regimen for progressive gastric cancer—construction of a clinical prediction model
Preoperative neoadjuvant chemotherapy is one of the most common treatments for patients with advanced gastric cancer that cannot be completely removed by surgery. Nab‐paclitaxel is a nano‐formulation of paclitaxel that has been shown to be effective in treating stomach cancer. In addition, oxaliplat...
Autores principales: | Feng, Long, Shao, Lei, Sun, Shuangshuang, Zhang, Chengwu, Cai, Baojia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315794/ https://www.ncbi.nlm.nih.gov/pubmed/37096925 http://dx.doi.org/10.1002/cam4.5977 |
Ejemplares similares
-
The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study
por: Zhang, Chenghai, et al.
Publicado: (2022) -
Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis
por: Tang, Chengwu, et al.
Publicado: (2020) -
Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021) -
Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2019) -
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
por: Zhang, Lingyun, et al.
Publicado: (2022)